Attovia Previews ATTO-1310 and ATTO-2306 Dermatology Posters

Key Takeaways

• Attovia plans to present interim ATTO-1310 data in patients with high-itch atopic dermatitis or chronic pruritus at the Fall Clinical Dermatology Conference.
• The ATTO-1310 study is a single-dose, randomized, double-blind, and placebo-controlled trial.
• The presentation on ATTO-2306 concerns preclinical characterization of an IL-13/IL-31 bispecific, not human treatment results.

Interleukin-31 (IL-31)–directed treatment is being investigated for patients with itch in atopic dermatitis and chronic pruritis. Attovia has announced two FCD presentations, one clinical and one preclinical, to be discussed at the 2026 Fall Clinical Dermatology Conference.

ATTO-1310 is an anti-IL-31 ATTOBODY-based candidate, described as an ATTOBODY-Fc fusion protein. The interim Phase 1b presentation covers a single-dose, randomized, double-blind, placebo-controlled study in patients with atopic dermatitis or chronic pruritus, with a placebo comparator. Attovia stated in its second-quarter 2026 update that ATTO-1310 demonstrated preliminary clinical proof of concept in these populations without reporting supporting data.

The second FCD presentation concerns ATTO-2306, a long-acting bispecific antibody directed against interleukin-13 (IL-13) and IL-31 for type 2 inflammatory skin diseases.

Clinician Questions

What study design is named for the ATTO-1310 Phase 1b presentation? The poster includes interim results from a randomized, double-blind, placebo-controlled study of a single dose of ATTO-1310 in patients with atopic dermatitis or chronic pruritus.

What development stage is ATTO-2306 at for atopic dermatitis? Attovia describes its long-acting IL-13/IL-31 bispecific ATTO-2306 as undergoing investigational new drug–enabling studies for atopic dermatitis and other immune-mediated skin diseases.